Ketoprofen

Ketoprofen

Cat. No.: PI22071154

Description: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin. It was patented in 1967 and approved for medical use in 1980.

Product Details
CAS 22071-15-4
Synonyms RP-19583
Molecular Formula C16H14O3
Molecular Weight 254.28
Therapeutic Category Non-Steroid Anti-Inflammatory
Available DMF/CEP/GMP CEP, JDMF, CADIFA, NMPA DMF, EUGMP
Uses (1) Ketoprofen is generally prescribed for arthritis-related inflammatory pains or severe toothaches that result in the inflammation of the gums.
(2) Ketoprofen topical patches are being used for treatment of musculoskeletal pain.
(3) Ketoprofen can also be used for treatment of some pain, especially nerve pain such as sciatica, postherpetic neuralgia and referred pain for radiculopathy, in the form of a cream, ointment, liquid, spray, or gel, which may also contain ketamine and lidocaine, along with other agents which may be useful, such as cyclobenzaprine, amitriptyline, acyclovir, gabapentin, orphenadrine and other drugs used as NSAIDs or adjuvant, atypical or potentiators for pain treatment.
Mechanism Of Action The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Case Study

Ketoprofen for the Synthesis of Ketoprofen-Based Mutual Prodrug for Enhanced Oral Bioavailability and Reduced Gastric Irritation

Optimizing therapeutics: A novel mutual prodrug of ketoprofen and Chlorzoxazone for enhanced efficacy and safety Salve KS, et al. Journal of the Indian Chemical Society, 2024, 101(12), 101471.

This study presents the synthesis and pharmacological evaluation of a novel mutual prodrug combining Ketoprofen (KF), a nonsteroidal anti-inflammatory drug (NSAID), with Chlorzoxazone (CZX), a skeletal muscle relaxant.
Synthesis of KF Acid Chloride
The acid chloride of KF was synthesized by reacting KF with an excess of thionyl chloride. The reaction mixture was heated for 2 hours in a round-bottom flask equipped with a water condenser. Upon completion of the reaction, the mixture was cooled to room temperature, and the excess thionyl chloride was removed. The resulting product was then washed with water to yield the acid halide of ketoprofen.
Synthesis of the Mutual Prodrug from Acid Chloride
In the next step, 0.77 mol of dry CZX, 0.84 mol of pure N,N-dimethylaniline, and anhydrous ether were placed into a flask and stirred. The mixture was gently refluxed on a water bath. Following this, 0.79 mol of redistilled KF acid chloride was added. The reaction was allowed to reflux vigorously, then rapidly cooled to room temperature. Approximately 10 mL of distilled water was added, and stirring was continued until the precipitate dissolved completely. The ether layer was separated and extracted with 10% sulfuric acid until the aqueous extract remained clear after alkalization with NaOH. The solution was then washed with 15 mL of saturated sodium bicarbonate solution, and the ether was dried over 1 g of anhydrous sodium sulfate overnight. The ether was removed by distillation using a fractionating column, and the final product was collected.

Photocatalytic Degradation of Ketoprofen (KET) Using TiO2 in Aqueous Media

Photocatalytic degradation of non-steroidal anti-inflammatory drugs with ketoprofen as model compound. Intermediates and total reaction mechanism Aguilar J, et al. Journal of Photochemistry and Photobiology A: Chemistry, 2025, 458, 115974.

This study investigates the photocatalytic degradation of Ketoprofen (KET) in aqueous media using titanium dioxide (TiO2) as a photocatalyst. The degradation mechanism was monitored using a combination of analytical techniques, including TOC, HPLC, UV-Vis, IR, 1H NMR, and HPLC-MS. Initial TOC measurements revealed that KET undergoes rapid transformation into intermediate compounds, achieving 70% mineralization after five hours of irradiation.
HPLC and UV-Vis analyses indicated that KET is quickly converted into aromatic intermediates such as 3-hydroxy-benzophenone, phenol, 1,4-hydroquinone, 1,2,4-benzenetriol, and catechol. These compounds undergo further degradation into lower molecular weight acids, as confirmed by IR and 1H NMR studies. The photocatalytic pathway involves two main routes: one where decarboxylation followed by oxidation occurs, and another where hydroxyl radicals insert into the aromatic rings of KET, producing hydroxylated derivatives.
The study identifies a complete photocatalytic degradation mechanism: initially, KET is transformed into benzophenone-like structures, which then degrade into polyhydroxylated aromatic compounds. These intermediates are strongly adsorbed onto the TiO2 surface and further oxidized, ultimately mineralizing into carbon dioxide and water.

* Our products are for research use only.

Get in Touch

We’re glad to help you with your products and services demands. For any inquiry, question or recommendation, please send an email to inquiry@alfa-chemistry.com or fill out the following form.

Verification code
For product and service inquiries icon1

For product and service inquiries, please use our online system or send an email to inquiry@alfa-chemistry.com.

For product and service inquiries icon2

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x